Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Medigene AG's enterprise value is $-10.64 Mil.
Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-14.98 Mil. Therefore, Medigene AG's EV-to-EBITDA for today is 0.71.
The historical rank and industry rank for Medigene AG's EV-to-EBITDA or its related term are showing as below:
MDGEF's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 12.78 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Medigene AG (OTCPK:MDGEF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medigene AG's PE Ratio (TTM) for today is calculated as:
Medigene AG's share price for today is $2.59.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.316.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Medigene AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDGEF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Medigene AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigene AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigene AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medigene AG's EV-to-EBITDA falls into.
Medigene AG's current Enterprise Value is $-10.64 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medigene AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-14.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medigene AG (MDGEF) has a EV-to-EBITDA of 0.71 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medigene AG.
Is Medigene AG's EV-to-EBITDA too high?
Medigene AG's current EV-to-EBITDA is 0.71. The Biotechnology industry median EV-to-EBITDA is 12.78. Medigene AG's value of 0.71 is 94.4% below this industry median. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's EV-to-EBITDA compare to VRTX and REGN?
Medigene AG's EV-to-EBITDA of 0.71 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBITDA is 12.78. Medigene AG's value of 0.71 is 94.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.78, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigene AG's current EV-to-EBITDA of 0.71 is 94.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Medigene AG. For the Biotechnology industry, the median EV-to-EBITDA is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigene AG's current EV-to-EBITDA is 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current EV-to-EBITDA of 0.71. The current EV-to-EBITDA is 0.71 and 94.4% below the Biotechnology industry median of 12.78. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Medigene AG (MDGEF), the current EV-to-EBITDA is 0.71 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score
Get the complete analysis for MDGEF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDGEF has been successfully added to your 
